Clinical Trial Search

Primary: Number of Participants With Cessation of Fever Within 24h of Initiation of Study Treatment With no Fever Recurrence Within Next 7 Days. — 25; 40 Participants

Primary: Number of Adverse Events (Focused on Side Effects From IVIG or Infliximab Administration) — 2; 3 events

Primary: Number of Participants With Adverse Events — 2; 3; 13 participants

Primary: The Number of Subjects in Each Arm That Have Persistent or Recrudescent Fever 24 Hours After Completion of the Intravenous Immunoglobulin (IVIG) Infusion — 11; 11…

Primary: Number of Participants With SAE — 4 Participants

Primary: Number of Participants With Treatment-related Adverse Events — 0 Participants

Primary: Determine the Predictive Value of Cardiolite® Rest and Stress MPI to Define Pediatric Populations With Kawasaki Disease at High and Low Risk of Developing Cardiac…

Primary: IVIG Refractory — 13; 22 Participants — p=.10

Primary: Defervescence Rate Within 48 Hours After the Start of the Study Drug Administration — 75.0; 33.3 percentage of patients

Primary: Number of Participants Needing Additional Anti-inflammatory Therapy Within the First Week of First Randomization — 10; 10; 14 Participants

Primary: Coronary Flow Reserve (CFR) — 1.77 ratio: peak to baseline CFV

Primary: Number of Subjects Achieving Pediatric American College of Rheumatology 30% (PedACR30) Response at Week 16 — 23 Participants

Primary: Percentage of Participants With Adverse Events (AEs), Including Serious AEs — 100; 100; 28; 48 percentage of participants

Primary: Time to Response to Treatment, as Determined by a Modified JIA ACR30 Requiring no Fever, Coupled With a Requirement for Corticosteroid Taper in Participants Who Are…

Primary: Number of Participants With Adverse Events — 6; 1; 1 participants

Primary: Number of Participants With Stable or no Lesions Developed Based on MRI Neurological Involvement of K-D Disease Following Ruloxitinib — 1; 0; 0 Participants